December 1999
CMAJ: Canadian Medical Association Journal;11/30/99 Supplement, Vol. 161, pS28
Academic Journal
The article focuses on the recommendations for the administration of inhaled agonists for asthma. The use of both short-acting and long-acting inhaled agonists require an anti-inflammatory medication. Only the short-acting agonists could be used for relief of acute symptoms. Both have side-effects. The efficacy and safety of agonists is discussed.


Related Articles

  • Mometasone Furoate in Children with Mild to Moderate Persistent Asthma. Milgrom, Henry // Pediatric Drugs;2010, Vol. 12 Issue 4, p213 

    The high prevalence of asthma in pediatric patients underscores the need for effective and safe treatment in this population. Current treatment guidelines recommend inhaled corticosteroids (ICSs) as a preferred treatment for the control of mild to moderate persistent asthma in patients of all...

  • Leukotriene-receptor antagonists and related compounds.  // CMAJ: Canadian Medical Association Journal;11/30/99 Supplement, Vol. 161, pS31 

    The article focuses on the role of cysteinyl leukotriene-receptor antagonists (LTRA) in the treatment of asthma. Cysteinel LTRA, which can be considered as an alternative to inhaled glucocorticosteroids, acts as biochemical mediators in asthma. They act on human airway obstruction. The studies...

  • Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Holt, Shaun; Suder, Aneta; Weatherall, Mark; Cheng, Soo; Shirtcliffe, Philippa; Beasley, Richard // BMJ: British Medical Journal (International Edition);8/4/2001, Vol. 323 Issue 7307, p253 

    Conclusions: In adolescent and adult patients with asthma, most of the therapeutic benefit of inhaled fluticasone is achieved with a total daily dose of 100-250 [Mu]g, and the maximum effect is achieved with a dose of around 500 {Mu]g/day. However, these findings were limited by the lack of data...

  • Inhaled glucocorticosteroids in adults and children.  // CMAJ: Canadian Medical Association Journal;11/30/99 Supplement, Vol. 161, pS24 

    The article focuses on the recommendations for the administration of inhaled glucocorticosteroids for asthma. The article offers the recommended dosage of inhaled glucocorticosteroids for children and adult patients. The dosage and duration of the increase must depend on the severity of the...

  • New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist. Koshak, Emad A. // Annals of Thoracic Medicine;Apr-Jun2010, Vol. 5 Issue 2, p65 

    The author focuses on the safety warnings concerning long-acting beta agonists (LABAs) released by the U.S. Food and Drug Administration (FDA) in February 2010. The FDA has issued warnings over the use of inhaled LABAs among asthmatics following several clinical trials that show such patients...

  • Long-Term Methotrexate Treatment in Corticosteroid-Dependent Asthma. Mullarkey, Michael F.; Lammert, Joyce K.; Blumenstein, Brent A. // Annals of Internal Medicine;4/15/90, Vol. 112 Issue 8, p577 

    Presents a study which examined the long-term efficacy and toxicity of low-dose methotrexate in patients with corticosteroid-dependent bronchial asthma. Characteristics of patients who participated in the study; Description of the adverse reactions of patients to methotrexate treatments;...

  • Detrimental effects of alβuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma. Lundblad, Lennart K. A.; Rinaldi, Lisa M.; Poynter, Matthew E.; Riesenfeld, Erik P.; Min Wu; Aimi, Steven; Barone, Leesa M.; Bates, Jason H. T.; Irvin, Charles G. // Respiratory Research;Mar2011, Vol. 12 Issue 3, p1 

    Background: Inhaled short acting β2-agonists (SABA), e.g. albuterol, are used for quick reversal of bronchoconstriction in asthmatics. While SABA are not recommended for maintenance therapy, it is not uncommon to find patients who frequently use SABA over a long period of time and there is a...

  • Tiotropium for uncontrolled asthma. Elliott, William T. // Primary Care Reports;Dec2010 Pharmacology, p1 

    This article discusses research being done on the use of tiotropium, an anticholinergic inhaler, to treat asthma. It references a study published in the "American Journal of Medicine" in 2010. The study covered 210 adults with asthma who were given the drug. It found that the drug is superior to...

  • Efficacy and Safety of Budesonide/Formeterol Combination Therapy in Asthma Patients. Jakopović, Marko; Pavičić, Fadila; Redžepi, Gzim; Pleština, Sanja; Janković, Mateja; Franić, Zrinka; Šamija, Mirko; Samaržija, Miroslav // Collegium Antropologicum;Jun2009, Vol. 33 Issue 2, p587 

    Budesonide/formoterol as single inhaler was developed for treating asthma patients who are not adequately controlled on glacocorticoides alone. The aim of this study was to evaluate efficacy, safety and patient/physician satisfaction of budesonide/formoterol therapy. Total of 268 asthma patients...


Read the Article


Sign out of this library

Other Topics